GW6471 (20 mg/kg intraperitoneally every other day for four weeks) reduced Caki-1 renal xenograft growth relative to vehicle in male athymic mice. Combining it with sunitinib did not show synergy. Body weight did not differ among groups; this finding does not establish general safety. [2]
In a separate AB1-Luc mesothelioma model, daily GW6471 at 10 mg/kg, alone or with ABT pretreatment, did not significantly reduce tumor bioluminescence. Tissue invasion remained evident in treated and control mice. This regimen did not establish antitumor efficacy in that model. [1]
No significant tumor-growth benefit in an AB1-Luc mesothelioma model
Animal study · Female BALB/c mice bearing intraperitoneal AB1-Luc mesothelioma; efficacy methods specify BALB/cJAusb, 10–12 weeks [1]
Daily GW6471, with or without ABT pretreatment, did not significantly reduce tumor bioluminescence versus the control groups. Histology showed tissue invasion in treated and control mice. This negative result is specific to this model and regimen.
Conditions shared by the study groups
- Treatment course
- Maximum 7 consecutive days, beginning day 4
- GW6471 alone
- Model: Female BALB/c, AB1-Luc mesothelioma
- Route: Intraperitoneal
- Frequency: Daily
- Vehicle: 40% PEG400 plus 60% of 12.5% Solutol HS-15 in saline
- GW6471 plus ABT
- Model: Female BALB/c, AB1-Luc mesothelioma
- Route: Both intraperitoneal
- Frequency: Daily; ABT 2 h before GW6471
- Vehicle: GW6471: PEG400/Solutol saline formulation; ABT: 0.9% saline
Methods and source locations
Compound reported in the paper: GW6471; Compound label in the paper: GW6471
Results concern the specified literature reagent. A12413 stereochemistry, purity and lot activity have not been established by these studies.
Figure 6B–E and caption; STAR Methods: Mouse PPARα and PPARγ inhibition assay, Mouse pharmacokinetic studies (cross-referenced dosing), GW6471 formulation preparation
AB1-Luc tumor bioluminescence over time: IVIS average radiance; two-way ANOVA with Dunnett multiple comparisons — Figure 6C–D and caption; Results: Dual inhibition of PPARα/γ does not result in significant anti-mesothelioma activity in vivo
GW6471 alone · Figure 6B–E; STAR Methods: Mouse PPARα and PPARγ inhibition assay and cross-referenced Mouse pharmacokinetic studies
GW6471 plus ABT · Figure 6B–E; STAR Methods: Mouse PPARα and PPARγ inhibition assay, Mouse pharmacokinetic studies and GW6471 formulation preparation
Reduced growth of Caki-1 renal xenografts
Animal study · Male athymic Nu/Nu mice, 8 weeks old, bearing subcutaneous Caki-1 tumors [2]
GW6471 treatment reduced tumor-volume fold change versus vehicle from day 7 through day 28. Sunitinib was an active comparator; the combination did not show synergy. Body-weight comparisons showed no difference, which does not establish general safety or PPARα-specific causality.
- GW6471 monotherapy
- Model: Male athymic Nu/Nu mice with Caki-1 tumors
- Route: Intraperitoneal
- Frequency: Every other day
- Treatment course: 4 weeks; euthanasia on day 28
- Vehicle: 4% DMSO in PBS
- Reported limits: Figure 5 and In Vivo Study do not state group size; no n inferred from other assays.
- GW6471 plus sunitinib
- Model: Male athymic Nu/Nu mice with Caki-1 tumors
- Route: GW6471 intraperitoneal; sunitinib oral gavage
- Frequency: GW6471 every other day; sunitinib 5 days/week
- Treatment course: 4 weeks
- Vehicle: GW6471 in 4% DMSO/PBS; sunitinib in vegetable oil
- Reported limits: Group size not stated at selected tumor-growth locations; no numerical synergy score reported there.
Methods and source locations
Compound reported in the paper: GW6471; Compound label in the paper: GW6471
Compound-level literature evidence only; no validation of an Adooq lot or stereoisomer composition.
Materials: GW6471 supplier; In Vivo Study and Statistical Analysis; Figures 5–6 and captions; corresponding Results paragraph
Tumor volume relative to day 1: Calipers; volume = length × width²/2; independent-samples t-test described in general statistics — Figure 5 and caption; Results: In Vivo Treatment of a Xenograft Mouse Model With the PPARα Antagonist GW6471 Attenuates RCC Growth
Animal body weight across the treatment course: Weekly weighing and weighing at euthanasia — Figure 6 and caption; Materials and Methods: In Vivo Study
GW6471 monotherapy · In Vivo Study; Figure 5 caption; corresponding Results paragraph
GW6471 plus sunitinib · In Vivo Study; Figure 5 caption; corresponding Results paragraph